查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2157180

CD19靶向CAR-T細胞療法市場：全球市場預測，2026-2032年

CD19-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，以 CD19 為標靶的 CAR-T 細胞療法市場將成長至 198.8 億美元，複合年成長率為 18.15%。

主要市場統計數據
基準年 2025 61.8億美元
預計年份：2026年 72.9億美元
預測年份 2032 198.8億美元
複合年成長率 (%) 18.15%

CD19標靶CAR-T療法：概述

CD19靶向嵌合體抗原受體T細胞療法是一種先進的細胞免疫療法，它透過基因改造患者的T細胞，使其能夠識別CD19蛋白。 CD19是一種在多種B細胞惡性腫瘤中表現的蛋​​白質。雖然該療法已在某些復發或難治性B細胞癌中得到臨床應用，但目前的研究正在探索其在早期治療階段、其他血液系統疾病、治療持續時間、門診給藥以及腫瘤學以外領域的潛在應用。

在臨床實務中，越來越傾向於更早、更安全、更方便的治療方法。

該領域正從高度專業化的挽救性治療轉向更廣泛地融入整個治療流程。關鍵變化包括：儘早轉診合格的患者、改善淋巴球清除和橋接策略、加強對細胞激素釋放症候群和免疫效應細胞相關神經毒性症候群的管理，以及更加重視長期監測。生產自動化、分散式血液採集和物流系統、標準化診療路徑以及對醫療保健系統的投資也在影響治療的可近性和醫療機構的營運準備。

人工智慧可以提高患者篩選、生產和監測效率。

人工智慧可以透過分析臨床數據、基因組數據、影像數據和生產數據，支持靶向CD19的CAR-T細胞療法的開發。其潛在應用包括識別最有可能對治療產生反應的患者、早期檢測復發和治療併發症、最佳化構建體和程式參數以及改進品管。由於治療決策涉及複雜的生物學因素和較高的臨床風險，因此將其引入常規臨床實踐需要具有代表性的資料集、前瞻性檢驗、可解釋的模型、網路安全措施以及明確的課責。

區域洞察：基礎設施和交通便利性推動普及

北美在細胞治療中心、專業診斷和監管途徑方面擁有豐富的經驗，但成本、容量和地理可及性仍然是重要的考量因素。歐洲擁有先進的腫瘤學網路和協調的監管活動，但各國的保險報銷和實施情況各不相同。在亞太地區，日本、韓國、中國和澳洲等市場擁有先進的治療能力，但基礎設施和經濟能力有顯著差異。在拉丁美洲，轉診系統、生產能力和監管合規性正在發展，但醫療服務的可近性仍然不穩定。中東正在投資建造三級醫療和精準醫療基礎設施，但非洲的進展主要集中在大型醫療中心，並受到專家招聘、物流和資金籌措等挑戰的限制。

團體洞察：協作塑造臨床與生產能力

鑑於東南亞國協能力建構進展不平衡，區域轉診網路、人力資源發展和標準協調尤為重要。金磚國家擁有重要的研究、製造和臨床體系，但在監管成熟度、報銷機制和醫療服務可近性方面存在顯著差異。歐盟受益於跨境科學和監管協調，但各國醫療衛生體系的決策仍影響相關措施的實施。七國集團成員國在臨床研究、基礎設施和政策方面擁有豐富的經驗。海灣合作理事會成員國正透過集中機構和國際夥伴關係擴展其先進的醫療衛生體系。北約成員國的醫療衛生體系各不相同，它們的合作可以增強專業供應鏈的韌性，儘管私人醫療機構的優先事項與北約的目標仍然存在差異。

國家概況：各國應對能力因治療途徑而異。

在美國和加拿大，轉診和細胞治療網路已經建立，但能否獲得治療取決於保險公司的政策、醫療機構的容量和地區因素。德國、法國、義大利、西班牙和英國提供先進的血液學服務，但報銷、轉診和跨境轉診安排因國家而異。澳洲和日本擁有先進的腫瘤學基礎設施，但人口分佈分散，需要強大的物流系統。中國和韓國正在不斷發展的框架內，提升其臨床、生產和監管能力。印度正在發展專科中心和本土專業技術，但治療費用和分銷仍然是關鍵挑戰。巴西和墨西哥正在加強先進的腫瘤學服務，但面臨地區差異。俄羅斯的治療能力取決於其國內研究、監管和專業基礎設施的覆蓋範圍。

產業領導者的優先行動：建立值得信賴、以證據為基礎的護理路徑

領導者應優先考慮可靠的臨床證據、透明的患者篩選標準以及能夠全面評估治療效果和潛在風險的治療後後續觀察。在營運層面，應改善轉診協調、檢體採集和運輸的可靠性、生產品管系統、設施認證以及人力資源開發。與醫院、監管機構、保險公司和病患團體夥伴關係將有助於實現公平的醫療服務取得和更高的醫療準備水準。人工智慧（AI）專案不應只是技術部署，而應從臨床定義的用例、獨立檢驗、人工監督和健全的資料管治入手。

調查方法：對標靶 CD19 的 CAR-T 療法的現況進行實證綜合分析。

本執行摘要整合了與CD19標靶CAR-T療法相關的既有臨床發現和結構性趨勢，包括治療的生物機制、醫療服務、生產製造、安全管理、監管、基礎設施和可近性。區域、群體和國家層級的具體考量均為定性分析，重點在於醫療體系、政策、研究活動和實施條件方面已顯現的差異。本概要未使用任何市場估算、預測、市場佔有率、預估或公司層面的比較資料。解讀本概要時，應結合目前的臨床指南、監管決策、同行評審的研究以及當地的保險報銷政策。

結論：永續進步取決於臨床價值和醫療保健系統的狀況。

針對CD19的CAR-T療法徹底改變了某些B細胞惡性腫瘤的治療選擇，但其更廣泛的影響並非僅取決於治療效果。持續的治療效果需要及時轉診、專業的醫療基礎設施、嚴格的安全控制、可靠的生產製造、長期的追蹤以及公平的資金籌措。那些將實證醫學研究與人才培養、監管和醫療服務投入相結合的地區和國家，將更有能力負責任地擴大這種療法的益處。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：CD19標靶CAR-T細胞療法市場：依產品類型分類

  • 同種異體移植
    • HLA相容
    • 萬能供體
  • 本土種植
    • 冷凍保存
    • 生的

第8章：CD19標靶CAR-T細胞療法市場：依適應症分類

  • 急性淋巴性白血病
  • 慢性淋巴性白血病
  • 瀰漫性大B細胞淋巴瘤
    • 耐火
    • 復發
  • 濾泡性淋巴瘤
  • 套細胞淋巴瘤

第9章：CD19標靶CAR-T細胞療法市場：依治療階段分類

  • 一線治療
  • 第二行
  • 從第三行開始

第10章：CD19標靶CAR-T細胞療法市場：依最終用戶分類

  • 診所
  • 醫院及專科醫療中心
  • 研究機構

第11章：CD19靶向CAR-T細胞療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：CD19標靶CAR-T細胞療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：CD19標靶CAR-T細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Allogene Therapeutics
  • Autolus Therapeutics plc
  • Bristol Myers Squibb Company
  • Cabaletta Bio
  • Caribou Biosciences Inc.
  • Carsgen Therapeutics
  • Cellectis
  • Fosun Kite Biotechnology Co. Ltd.
  • Immuneel Therapeutics Pvt. Ltd.
  • ImmunoACT Pvt. Ltd.
  • JW Therapeutics
  • Kite Pharma Inc.
  • Legend Biotech Corporation
  • Lyell Immunopharma
  • Mustang Bio Inc.
  • Novartis AG
  • Precision BioSciences Inc.
  • Servier Laboratories
  • Wugen

第16章 主要專家

Product Code: MRR-EF0BD2D829D8

The CD19-targeted CAR-T Cell Therapy Market is projected to grow by USD 19.88 billion at a CAGR of 18.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.18 billion
Estimated Year [2026] USD 7.29 billion
Forecast Year [2032] USD 19.88 billion
CAGR (%) 18.15%

CD19-Targeted CAR-T Therapy: Executive Overview

CD19-targeted chimeric antigen receptor T-cell therapy is an advanced cellular immunotherapy in which a patient's T cells are genetically modified to recognize CD19, a protein expressed on many B-cell malignancies. Its clinical use is established in selected relapsed or refractory B-cell cancers, while ongoing research is examining earlier treatment lines, additional hematologic diseases, durability, outpatient delivery, and applications beyond oncology.

Clinical Practice Is Shifting Toward Earlier, Safer, and More Accessible Use

The field is moving from highly specialized rescue treatment toward broader integration across treatment pathways. Important shifts include earlier referral for eligible patients, improved lymphodepletion and bridging strategies, stronger management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and greater attention to long-term monitoring. Manufacturing automation, decentralized collection and logistics, standardized care pathways, and health-system investment are also shaping access and operational readiness.

Artificial Intelligence Is Strengthening Selection, Manufacturing, and Monitoring

Artificial intelligence can support CD19-targeted CAR-T development by analyzing clinical, genomic, imaging, and manufacturing data. Potential applications include identifying patients most likely to respond, detecting relapse or treatment complications earlier, optimizing construct and process parameters, and improving quality control. Translation into routine care requires representative datasets, prospective validation, explainable models, cybersecurity safeguards, and clear accountability because treatment decisions involve complex biology and high clinical risk.

Regional Insights: Infrastructure and Access Determine Adoption

North America has extensive experience with cellular-therapy centers, specialized diagnostics, and regulatory pathways, although cost, capacity, and geographic access remain important considerations. Europe is supported by sophisticated oncology networks and coordinated regulatory activity, with variation in reimbursement and national implementation. Asia-Pacific combines advanced capabilities in markets such as Japan, South Korea, China, and Australia with substantial differences in infrastructure and affordability. Latin America is developing referral, manufacturing, and regulatory capacity but faces uneven access. The Middle East is investing in tertiary-care and precision-medicine infrastructure, while Africa's progress is concentrated in leading centers and constrained by specialist capacity, logistics, and financing.

Group Insights: Collaboration Shapes Clinical and Manufacturing Capacity

ASEAN countries are building capability unevenly, making regional referral networks, workforce development, and harmonized standards particularly valuable. BRICS members span major research, manufacturing, and clinical systems but differ considerably in regulatory maturity, reimbursement, and access. The European Union benefits from cross-border scientific and regulatory coordination, while national health-system decisions continue to influence implementation. G7 members contribute substantial clinical research, infrastructure, and policy experience. GCC countries are expanding advanced-care capacity through centralized institutions and international partnerships. NATO members represent a broad set of health systems whose cooperation can support resilience in specialized supply chains, although civilian clinical priorities remain distinct from alliance objectives.

Country Insights: National Capacity Varies Across the Treatment Pathway

The United States and Canada have established referral and cellular-therapy networks, with access shaped by payer policy, center capacity, and geography. Germany, France, Italy, Spain, and the United Kingdom have advanced hematology services, while reimbursement, commissioning, and cross-border referral arrangements differ. Australia and Japan maintain sophisticated oncology infrastructure with geographically dispersed populations requiring strong logistics. China and South Korea are expanding clinical, manufacturing, and regulatory capabilities within evolving frameworks. India is developing specialized centers and domestic expertise while affordability and distribution remain important. Brazil and Mexico are strengthening advanced oncology services but face regional disparities. Russia's capacity is shaped by domestic research, regulation, and access to specialized infrastructure.

Action Priorities for Industry Leaders: Build Reliable, Evidence-Led Care Pathways

Leaders should prioritize durable clinical evidence, transparent patient-selection criteria, and post-treatment surveillance that captures both benefit and late risk. Operationally, they should strengthen referral coordination, collection and transport reliability, manufacturing quality systems, center accreditation, and workforce training. Partnerships with hospitals, regulators, payers, and patient organizations can improve equitable access and preparedness. Artificial-intelligence programs should begin with clinically defined use cases, independent validation, human oversight, and robust data governance rather than technology deployment alone.

Research Methodology: Evidence-Based Synthesis of the CD19 CAR-T Landscape

This executive summary synthesizes established clinical knowledge and structural trends relevant to CD19-targeted CAR-T therapy, including treatment biology, care delivery, manufacturing, safety management, regulation, infrastructure, and access. Regional, group, and country discussions are qualitative and focus on documented differences in healthcare capacity, policy, research activity, and implementation conditions. No market estimates, market shares, forecasts, or company-level comparisons are used. Findings should be interpreted alongside current clinical guidelines, regulatory decisions, peer-reviewed studies, and local reimbursement policies.

Conclusion: Sustainable Progress Depends on Clinical Value and System Readiness

CD19-targeted CAR-T therapy has reshaped treatment options for selected B-cell malignancies, but its broader impact depends on more than therapeutic efficacy. Consistent outcomes require timely referral, specialized infrastructure, disciplined safety management, reliable manufacturing, long-term follow-up, and equitable financing. Regions and countries that align evidence generation with workforce, regulatory, and care-delivery investment will be better positioned to extend the benefits of this therapy responsibly.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CD19-targeted CAR-T Cell Therapy Market, by Product Type

  • 7.1. Introduction
  • 7.2. Allogeneic
    • 7.2.1. Hla Matched
    • 7.2.2. Universal Donor
  • 7.3. Autologous
    • 7.3.1. Cryopreserved
    • 7.3.2. Fresh

8. CD19-targeted CAR-T Cell Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Acute Lymphoblastic Leukemia
  • 8.3. Chronic Lymphocytic Leukemia
  • 8.4. Diffuse Large B-Cell Lymphoma
    • 8.4.1. Refractory
    • 8.4.2. Relapsed
  • 8.5. Follicular Lymphoma
  • 8.6. Mantle Cell Lymphoma

9. CD19-targeted CAR-T Cell Therapy Market, by Line Of Therapy

  • 9.1. Introduction
  • 9.2. First-Line
  • 9.3. Second-Line
  • 9.4. Third-Line & Beyond

10. CD19-targeted CAR-T Cell Therapy Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals & Specialty Centers
  • 10.4. Research Institutes

11. CD19-targeted CAR-T Cell Therapy Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. CD19-targeted CAR-T Cell Therapy Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. CD19-targeted CAR-T Cell Therapy Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Allogene Therapeutics
  • 15.2. Autolus Therapeutics plc
  • 15.3. Bristol Myers Squibb Company
  • 15.4. Cabaletta Bio
  • 15.5. Caribou Biosciences Inc.
  • 15.6. Carsgen Therapeutics
  • 15.7. Cellectis
  • 15.8. Fosun Kite Biotechnology Co. Ltd.
  • 15.9. Immuneel Therapeutics Pvt. Ltd.
  • 15.10. ImmunoACT Pvt. Ltd.
  • 15.11. JW Therapeutics
  • 15.12. Kite Pharma Inc.
  • 15.13. Legend Biotech Corporation
  • 15.14. Lyell Immunopharma
  • 15.15. Mustang Bio Inc.
  • 15.16. Novartis AG
  • 15.17. Precision BioSciences Inc.
  • 15.18. Servier Laboratories
  • 15.19. Wugen

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global CD19-targeted CAR-T Cell Therapy Market, Years Considered for the Study
  • FIGURE 2. Global CD19-targeted CAR-T Cell Therapy Market, Research Design
  • FIGURE 3. Global CD19-targeted CAR-T Cell Therapy Market, Research Framework
  • FIGURE 4. Global CD19-targeted CAR-T Cell Therapy Market, Data Triangulation
  • FIGURE 5. Global CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2032 (%)
  • FIGURE 11. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global CD19-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global CD19-targeted CAR-T Cell Therapy Market Segmentation & Coverage
  • TABLE 2. Global CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Hla Matched Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Hla Matched Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Hla Matched Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Universal Donor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Universal Donor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Universal Donor Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Cryopreserved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Cryopreserved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Cryopreserved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Fresh Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Fresh Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Fresh Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 23. Global Acute Lymphoblastic Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Acute Lymphoblastic Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Acute Lymphoblastic Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Chronic Lymphocytic Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Chronic Lymphocytic Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Chronic Lymphocytic Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Diffuse Large B-Cell Lymphoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Diffuse Large B-Cell Lymphoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Diffuse Large B-Cell Lymphoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Refractory Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Refractory Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Refractory Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Relapsed Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Relapsed Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Relapsed Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Follicular Lymphoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Follicular Lymphoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Follicular Lymphoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Mantle Cell Lymphoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Mantle Cell Lymphoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Mantle Cell Lymphoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 45. Global First-Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global First-Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global First-Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Second-Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Second-Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Second-Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Third-Line & Beyond Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Third-Line & Beyond Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Third-Line & Beyond Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Hospitals & Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Hospitals & Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Hospitals & Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 73. North America CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. North America CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 75. North America CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 76. North America CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 77. North America CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 78. North America CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 79. North America CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 80. North America CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 81. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 83. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 84. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 85. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 86. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 87. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 88. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 91. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 92. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 93. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 94. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 95. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 96. Europe CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 99. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 100. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 101. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 102. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 103. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 104. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 105. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 107. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 108. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 109. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 110. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 111. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 112. Africa CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 113. Global CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 116. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 117. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 118. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 119. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 120. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 121. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 124. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 125. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 126. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 127. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 128. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 129. GCC CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 130. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 132. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 133. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 134. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 135. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 136. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 137. European Union CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 138. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 139. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 140. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 141. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 142. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 143. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 144. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 145. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 148. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 149. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 150. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 151. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 152. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 153. G7 CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 154. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 155. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 156. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 157. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 158. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 159. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 160. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 161. NATO CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 162. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 163. United States CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 164. United States CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 165. United States CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 166. United States CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 167. United States CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 168. United States CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 169. United States CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 170. United States CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. Canada CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 172. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 173. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 174. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 175. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 176. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 177. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 178. Canada CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. Mexico CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 180. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 181. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 182. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 183. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 184. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 185. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 186. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. Brazil CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 188. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 189. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 190. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 191. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 192. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 193. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 194. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 195. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 196. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 197. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 198. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 199. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 200. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 201. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 202. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. Germany CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 204. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 205. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 206. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 207. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 208. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 209. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 210. Germany CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. France CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 212. France CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 213. France CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 214. France CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 215. France CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 216. France CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 217. France CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 218. France CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 219. Russia CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 220. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 221. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 222. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 223. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 224. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 225. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 226. Russia CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 227. Italy CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 228. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 229. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 230. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 231. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 232. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 233. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 234. Italy CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 235. Spain CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 236. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 237. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 238. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 239. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 240. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 241. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 242. Spain CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 243. China CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 244. China CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 245. China CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 246. China CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 247. China CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 248. China CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 249. China CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 250. China CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. India CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 252. India CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 253. India CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 254. India CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 255. India CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 256. India CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 257. India CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 258. India CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 259. Japan CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 260. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 261. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 262. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 263. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 264. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 265. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 266. Japan CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 267. Australia CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 268. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 269. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 270. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 271. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 272. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 273. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 274. Australia CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 275. South Korea CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
  • TABLE 276. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 277. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
  • TABLE 278. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
  • TABLE 279. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 280. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
  • TABLE 281. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 282. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 283. Global CD19-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025
  • TABLE 284. Global CD19-targeted CAR-T Cell Therapy Market, Key Experts